

Charlotte Benson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3947534/publications.pdf>

Version: 2024-02-01

55
papers

1,146
citations

394421

19
h-index

414414

32
g-index

55
all docs

55
docs citations

55
times ranked

1814
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic treatment of soft-tissue sarcoma – gold standard and novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 187-202.	27.6	185
2	Uterine sarcoma – current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 597-606.	2.6	86
3	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	1.3	54
4	Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. <i>Gynecologic Oncology</i> , 2016, 142, 89-94.	1.4	54
5	Desmoplastic Small Round Cell Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 672-684.	0.8	50
6	Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature. <i>Clinical Sarcoma Research</i> , 2013, 3, 14.	2.3	49
7	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. <i>British Journal of Cancer</i> , 2017, 116, 669-678.	6.4	48
8	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014, 4, 7.	2.3	47
9	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 – CaboGIST™. <i>European Journal of Cancer</i> , 2020, 134, 62-74.	2.8	42
10	Pazopanib, a promising option for the treatment of aggressive fibromatosis. <i>Anti-Cancer Drugs</i> , 2017, 28, 421-426.	1.4	36
11	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. <i>Annals of Surgical Oncology</i> , 2019, 26, 4699-4706.	1.5	36
12	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	6.4	33
13	Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. <i>Clinical Sarcoma Research</i> , 2013, 3, 13.	2.3	32
14	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017, 56, 1769-1775.	1.8	29
15	Desmoplastic small round cell tumour: the radiological, pathological and clinical features. <i>Insights Into Imaging</i> , 2013, 4, 111-118.	3.4	28
16	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	2.5	26
17	Angiosarcoma of the face and scalp: Effective systemic treatment in the older patient. <i>Journal of Geriatric Oncology</i> , 2014, 5, 276-280.	1.0	22
18	Elicitation of health state utilities in soft tissue sarcoma. <i>Quality of Life Research</i> , 2013, 22, 1697-1706.	3.1	21

#	ARTICLE	IF	CITATIONS
19	Role of expert centres in the management of sarcomas – A UK perspective. <i>European Journal of Cancer</i> , 2014, 50, 1951-1956.	2.8	21
20	Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 147-151.	1.3	21
21	DOG1 Expression in Low-Grade Fibromyxoid Sarcoma. <i>International Journal of Surgical Pathology</i> , 2015, 23, 454-460.	0.8	18
22	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	6.4	17
23	Update on imatinib for gastrointestinal stromal tumors: duration of treatment. <i>OncoTargets and Therapy</i> , 2013, 6, 1011.	2.0	16
24	Fistulation as a complication of intra-abdominal soft-tissue sarcomas; a case series. <i>Journal of Radiology Case Reports</i> , 2013, 7, 15-21.	0.4	16
25	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	2.5	14
26	First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. <i>Clinical Sarcoma Research</i> , 2015, 5, 10.	2.3	13
27	Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. <i>BMC Cancer</i> , 2017, 17, 717.	2.6	13
28	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. <i>Anticancer Research</i> , 2019, 39, 4891-4896.	1.1	13
29	Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on survival.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10545-10545.	1.6	13
30	Effective Downsizing of a Large Oesophageal Gastrointestinal Stromal Tumour with Neoadjuvant Imatinib Enabling an Uncomplicated and without Tumour Rupture Laparoscopic-Assisted Ivor-Lewis Oesophagectomy. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-6.	0.3	12
31	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. <i>Clinical Oncology</i> , 2020, 32, e27-e35.	1.4	12
32	Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100737.	0.6	9
33	Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11006-11006.	1.6	9
34	Six-year survival of a patient with pulmonary artery angiosarcoma. <i>Asian Cardiovascular and Thoracic Annals</i> , 2012, 20, 728-730.	0.5	8
35	Antiangiogenic approach in soft-tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 975-982.	2.4	7
36	New drugs in sarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 221-229.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. <i>Journal of Surgical Oncology</i> , 2020, 122, 691-698.	1.7	7
38	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. <i>Future Oncology</i> , 2021, 17, 2659-2670.	2.4	6
39	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
40	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. <i>Anticancer Research</i> , 2020, 40, 7003-7007.	1.1	3
41	Pazopanib as a choice for advanced solitary fibrous tumour. <i>Lancet Oncology</i> , The, 2020, 21, 332-333.	10.7	2
42	Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11518-11518.	1.6	2
43	A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10038-10038.	1.6	2
44	Treatment options for leiomyosarcoma. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 413-422.	0.8	1
45	Current and advancing systemic treatment options for soft tissue sarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2023-2037.	1.8	1
46	Clinical management of aggressive fibromatosis/desmoid tumour. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1027-1036.	0.8	0
47	The Value of Anti-Angiogenics in Soft Tissue Sarcoma Therapy. , 2017, , 1-10.		0
48	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , 2019, 39, 347-351.	1.1	0
49	Treatment outcomes of primary mediastinal and intrathoracic great vessels sarcoma: Royal Marsden Hospital experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10060-10060.	1.6	0
50	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e21516-e21516.	1.6	0
51	Influence of chemotherapy combined with radiotherapy on the time-to-development of radiation-induced sarcomas: A multicenter, retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11046-11046.	1.6	0
52	Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11559-11559.	1.6	0
53	Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23519-e23519.	1.6	0
54	The Value of Anti-angiogenics in Soft Tissue Sarcoma Therapy. , 2019, , 465-473.		0

#	ARTICLE	IF	CITATIONS
55	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202.. Journal of Clinical Oncology, 2020, 38, 11556-11556.	1.6	0